Early weight gain as a predictor of substantial weight gain with olanzapine/fluoxetine combination: An analysis of 2 adult studies in treatment-resistant depression

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 337-340

  Degenhardt, Elisabeth K ^a   Jamal, Hassan H ^a   Tormey, Susan ^a   Case, Michael ^a  

^a Lilly USA   (United States)

Author keywords

fluoxetine; OFC; olanzapine; predictor; weight gain

Indexed keywords

FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; OLANZAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DISEASE RESISTANCE; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY WEIGHT GAIN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SUBSTANTIAL WEIGHT GAIN; SUSBTANTIAL WEIGHT GAIN; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; WEIGHT GAIN;

BENZODIAZEPINES; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSION; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TIME FACTORS; WEIGHT GAIN;

EID: 79955615606     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182196e64     Document Type: Article

References (32)

1. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007;100:395-404. (Pubitemid 47062891)
2. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-220. (Pubitemid 29193917)
3. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, et al. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101-107.
4. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res. 2009;43:620-626.
5. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. (Pubitemid 41345943)
7. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001;62:231-238. (Pubitemid 32428761)
8. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62:92-100. (Pubitemid 32199865)
9. Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25:255-258. (Pubitemid 40685790)
10. Ujike H, Nomura A, Morita Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry. 2008;69:1416-1422.
11. Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, et al. Olanzapine-induced weight gain is associated with the j759C/T and j697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J. 2009;9:234-241.
12. Treuer T, Hoffmann VP, Chen AK, et al. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry. 2009;10:729-740.
13. Lipkovich I, Jacobson JG, Hardy TA, et al. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry. 2008;8:78.
14. Hennen J, Perlis RH, Sachs G, et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry. 2004;65:1679-1687.
15. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry. 2009;70:387-396.
16. Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry. 2005;66:1468-1476. (Pubitemid 41779547)
17. Olanzapine [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009.
18. Symbyax [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009.
19. Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry. 2008;42:369-381. (Pubitemid 351877210)
20. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatmentVpharmacological mechanisms. Pharmacol Ther. 2010;125:169-179.
21. Hoffmann VP, Ahl J, Meyers A, et al. Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry. 2005;66:1576-1579. (Pubitemid 43068698)
22. Khazaal Y, Fresard E, Rabia S, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res. 2007;91:169-177.
23. Vreeland B. Treatment decisions in major mental illness: weighing the outcomes. J Clin Psychiatry. 2007;68(suppl 12):5-11. (Pubitemid 350021617)
24. Lindenmayer JP, Khan A, Wance D, et al. Outcome evaluation of a structured educational wellness program in patients with severe mental illness. J Clin Psychiatry. 2009;70:1385-1396.
25. Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26:316-320. (Pubitemid 43804625)
26. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131-134. (Pubitemid 32047260)
27. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66:1289-1297. (Pubitemid 41546509)
28. Corya SA,Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23:364-372. (Pubitemid 44619788)
29. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68:224-236. (Pubitemid 46362643)
30. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25:250-254. (Pubitemid 40685789)
31. Weight-Control Information Network. Weight Loss for Life. NIH Publication No. 04-3700. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. Available at: http:// win.niddk.nih.gov/publications/PDFs/ WeightLossforLife-04.pdf. Accessed February 22, 2010.
32. Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol. 2006;26:128-134.